In addition, surgery and chemoradiation can negatively impact the quality of life, so balancing quality of life with survival benefits is an important consideration during clinical care.16–18 Moreover, patients with IDH-mutant gliomas are considerably younger and have better prognosis than patients with IDH-wild-type gliomas.2 Thus, novel targeted therapies for IDH-mutant gliomas that circumvent the toxicities associated with chemoradiation may provide significant benefits for a younger patient population in terms of reduced morbidity. This evidence concerns the gene IDH1 and glioma.